IHC News and Research

RSS

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

Human tumors with MET amplification respond to MET inhibitor drugs

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research.

3 Jun 2013

New 3-D technology to see precise source of atrial fibrillation in the heart

Researchers at the Intermountain Heart Institute at Intermountain Medical Center have developed a new 3-D technology that for the first time allows cardiologists the ability to see the precise source of atrial fibrillation in the heart - a breakthrough for a condition that affects nearly three million Americans.

13 May 2013

Researchers find tumors with ALK rearrangements can harbor additional mutations

The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment.

23 Apr 2013

Previously unknown cell discovered in the urethra of mice

A recent study conducted by a group of German scientists revealed the presence of a previously unknown cell in the urethra of mice. These chemosensory cholinergic brush cells are in close contact to sensory neurons that express cholinergic receptors.

15 Mar 2013

Pitavastatin may reduce risk of heart attack, stroke and death in patients with high cholesterol

Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City.

12 Mar 2013

IL-22 plays critical role in normal lung repair following influenza infection

Once the initial episode of influenza has passed, the chronic effects tend to be overlooked. The results of a new study indicate that the cytokine interleukin-22 (IL-22) plays a critical role in normal lung repair following influenza infection. This study is published in the April 2013 issue of the American Journal of Pathology.

11 Mar 2013

New tool uses evidence-based care to improve quality of care for heart failure patients

Researchers at the Intermountain Heart Institute at Intermountain Medical Center have developed an innovative tool designed to eliminate 30-day hospital readmissions for heart failure patients and improve the quality of medical care a patient receives in the hospital.

11 Mar 2013

Intermountain Risk Score tool can predict mortality among trauma patients

A simple, inexpensive blood test performed on trauma patients upon admission can help doctors easily identify patients at greatest risk of death, according to a new study by researchers at Intermountain Medical Center in Salt Lake City.

18 Jan 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

DNA adducts linked to oral cancer in smokers

Having a high susceptibility to certain types of DNA damage caused by tobacco smoking could significantly increase the risk for oral cancer, show results of a Taiwanese study.

28 Dec 2012

Immunohistochemistry reliable in identifying ALK rearrangement: Study

Favorable results have led to crizotinib gaining approval for the treatment of advanced stage ALK-positive non-small cell lung cancer (NSCLC) in Japan, the United States, Canada, and several other countries in Europe and Asia.

17 Dec 2012

New diagnostic assay for screening ALK fusions in non-small cell lung carcinoma

Approximately one in 20 patients with non-small cell lung carcinoma (NSCLC) has chromosomal aberrations targeting the anaplastic lymphoma kinase (ALK) gene. This has considerable implications for treatment because these patients are highly responsive to ALK-specific kinase inhibitors such as crizotinib.

From NanoString Technologies 13 Dec 2012

Study examines association between ischemic-hypoxic conditions and ADHD

Children who had in-utero exposure to ischemic-hypoxic conditions, situations during which the brain is deprived of oxygen, were significantly more likely to develop attention deficit hyperactivity disorder later in life as compared to unexposed children, according to a Kaiser Permanente study published in the journal Pediatrics.

10 Dec 2012